1. Advances in targeted alpha therapy for prostate cancer. (16th August 2019) Authors: De Vincentis, G; Gerritsen, W; Gschwend, J E; Hacker, M; Lewington, V; O'Sullivan, J M; Oya, M; Pacilio, M; Parker, C; Shore, N; Sartor, O Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Now the dust has settled over immune checkpoint blockade in metastatic prostate cancer. (10th July 2018) Authors: Mehra, N; Gerritsen, W Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1620 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. (3rd May 2019) Authors: Fradet, Y; Bellmunt, J; Vaughn, D J; Lee, J L; Fong, L; Vogelzang, N J; Climent, M A; Petrylak, D P; Choueiri, T K; Necchi, A; Gerritsen, W; Gurney, H; Quinn, D I; Culine, S; Sternberg, C N; Nam, K; Frenkl, T L; Perini, R F; de Wit, R; Bajorin, D F Journal: Annals of oncology Issue: Volume 30:Number 6(2019) Page Start: 970 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗